Key result
Celecoxib confers cardiovascular risk that varies across dosing regimens and baseline patient risk.
Why the study?
The extent of celecoxib-related cardiovascular risk and its variation by dose regimen and baseline cardiovascular risk were unclear.
Does celecoxib affect cardiovascular risk compared to placebo?
Does celecoxib affect cardiovascular risk compared to placebo?
Cardiovascular risk associated with celecoxib depends on the dose regimen and the patient's baseline cardiovascular risk.
Supports risk-stratified celecoxib prescribing by dose and baseline CV risk; extends meta-analytic evidence on NSAID safety heterogeneity.
We observed evidence of differential cardiovascular risk as a function of celecoxib dose regimen and baseline cardiovascular risk. By further clarifying the extent of celecoxib-related cardiovascular risk, these findings may help guide treatment decisions for patients who derive clinical benefit from selective cyclooxygenase-2 inhibition.
No takes yet. Share an insight, caveat, or question.
Solomon et al. (2008) studied this question. Celecoxib confers a differential cardiovascular risk that varies depending on the specific dose regimen and the patient's baseline cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: